Posted in | News

Cytec and DSM to Terminate Melamine Joint Venture

Cytec Industries Inc. and Royal DSM N.V. announced today that agreement had been reached for the early termination of their 50/50 manufacturing joint venture American Melamine Industries (“AMEL”) as well as the dismissal of all legal action between the parties concerning this joint venture.

Upon closing of the transaction, which is expected on August 1, 2006, Cytec will assume 100% ownership of the assets and liabilities of AMEL and receive $7.4 million (approximately €5.9 million) for releasing all past and future obligations under various partnership agreements.

David Lilley, Cytec Chairman, President and Chief Executive Officer stated, “We are pleased to have entered into this latest agreement with DSM, our long-term partner in melamine manufacturing. Since being formed in 1986, we have worked closely with DSM and very much respect their decision to end our joint venture. We will continue to operate the melamine plant for both our internal use and sale to third party customers.” Commenting on Cytec’s earnings, Lilley stated, “The payment to be received roughly approximates cost reimbursements which we had expected to receive from DSM from mid-year through year-end and thus the receipt of this payment does not materially impact our most recent earnings forecast dated July 20, 2006.”

Jan Zuidam, DSM Deputy Chairman stated, “We are also pleased to have worked out an amicable agreement with Cytec. We have a long standing relationship with Cytec encompassing many business areas and we look forward to continue working with them. It goes without saying that we will continue to serve our melamine customers in the Americas in the same way as before from our other plants in the world.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.